Technical Momentum and Indicator Analysis
Lupin’s current price stands at ₹2,449.80, up 2.30% from the previous close of ₹2,394.70, with intraday highs reaching ₹2,463.00 and lows at ₹2,401.70. The stock is trading close to its 52-week high of ₹2,530.00, a strong signal of upward momentum, while comfortably above its 52-week low of ₹1,838.65. This price action reflects a robust recovery and sustained buying interest.
The Moving Average Convergence Divergence (MACD) indicator presents a bullish signal on both weekly and monthly timeframes, indicating that the stock’s short-term momentum is aligned with its longer-term trend. This dual timeframe bullishness suggests that Lupin is in a phase of sustained upward price movement, supported by increasing buying pressure.
Conversely, the Relative Strength Index (RSI) offers a mixed picture. While the weekly RSI does not currently signal any extreme conditions, the monthly RSI is bearish, hinting at some underlying caution or potential overextension in the longer term. This divergence between weekly and monthly RSI readings suggests that while short-term momentum is positive, investors should monitor for any signs of weakening strength over the coming months.
Bollinger Bands reinforce the bullish narrative, showing expansion and upward price movement on both weekly and monthly charts. This indicates increased volatility accompanied by a positive price trend, often a precursor to continued gains.
Moving Averages and Trend Confirmation
Daily moving averages are firmly bullish, with the stock price trading above key averages such as the 50-day and 200-day moving averages. This alignment confirms the positive short-term trend and supports the technical upgrade from mildly bullish to bullish. The KST (Know Sure Thing) indicator adds nuance, showing a bullish signal on the weekly chart but only mildly bearish on the monthly, reinforcing the mixed medium-term outlook.
Dow Theory analysis reveals no clear trend on the weekly scale but confirms a bullish trend on the monthly timeframe. This suggests that while short-term price fluctuations may lack a definitive directional bias, the broader monthly trend remains positive.
On the volume front, the On-Balance Volume (OBV) indicator shows no significant trend weekly but a mildly bearish stance monthly. This could imply that despite price gains, volume support is not yet fully convincing over the longer term, warranting cautious optimism.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Comparative Performance and Market Context
Lupin’s recent returns have outpaced the Sensex significantly across multiple time horizons. Over the past week, Lupin gained 1.83% compared to the Sensex’s 1.17%. The one-month return stands at 1.76% versus 1.21% for the benchmark. More impressively, year-to-date returns for Lupin are 15.99%, while the Sensex has declined by 8.88%. Over the last year, Lupin’s stock has surged 23.48%, contrasting with a 4.53% decline in the Sensex.
Longer-term performance further highlights Lupin’s strength. Over three years, the stock has appreciated by 151.55%, vastly outperforming the Sensex’s 17.37%. Even over five years, Lupin’s return of 125.65% dwarfs the Sensex’s 47.48%. However, over a decade, Lupin’s 40.73% gain trails the Sensex’s 176.82%, reflecting the broader market’s extended bull run during that period.
This relative outperformance, especially in recent years, underscores Lupin’s growing prominence within the Pharmaceuticals & Biotechnology sector and its ability to generate shareholder value amid market volatility.
Mojo Score and Analyst Ratings
MarketsMOJO assigns Lupin a Mojo Score of 77.0, categorising it as a Buy. This represents a slight downgrade from its previous Strong Buy rating as of 28 July 2026, reflecting the nuanced technical signals and mixed monthly momentum indicators. The mid-cap stock’s technical trend upgrade from mildly bullish to bullish aligns with this rating, suggesting that while the stock remains attractive, investors should remain vigilant for potential short-term fluctuations.
The company’s standing within the Pharmaceuticals & Biotechnology sector, combined with its technical and fundamental metrics, makes it a compelling candidate for investors seeking exposure to mid-cap growth with a solid technical foundation.
Thinking about Lupin Ltd.? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this mid-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Investor Takeaway and Outlook
In summary, Lupin Ltd. is exhibiting a clear shift towards stronger bullish momentum, supported by multiple technical indicators and a favourable price trajectory. The MACD’s bullish stance on both weekly and monthly charts, combined with daily moving averages signalling upward momentum, provides a solid foundation for continued gains. However, the mixed signals from the monthly RSI and OBV suggest that investors should monitor volume trends and potential overbought conditions carefully.
The stock’s recent outperformance relative to the Sensex and its sector peers further bolsters its appeal, particularly for investors seeking mid-cap exposure in the Pharmaceuticals & Biotechnology space. The slight downgrade from Strong Buy to Buy by MarketsMOJO reflects a balanced view, acknowledging both the positive technical momentum and the need for caution given some longer-term bearish signals.
Overall, Lupin’s technical and fundamental profile suggests it remains a strong candidate for accumulation, especially for investors with a medium to long-term horizon who can tolerate some volatility. Continued monitoring of key technical indicators and volume patterns will be essential to capitalise on the stock’s bullish trend while managing risk effectively.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
